首页> 外文学位 >Effects of adenine nucleotide agents and their therapeutic potential on triple negative breast cancer.
【24h】

Effects of adenine nucleotide agents and their therapeutic potential on triple negative breast cancer.

机译:腺嘌呤核苷酸试剂及其对三阴性乳腺癌的治疗潜力。

获取原文
获取原文并翻译 | 示例

摘要

Breast cancer (BCa) is the most frequently diagnosed non-cutaneous cancer in the United States and the second leading cause of cancer death of American women. Over the last several decades, enhancement of BCa screening and early detection improved patients survival rate and patients' well-being. However, some aggressive types of BCa still threaten BCa patients' well- being. Triple negative breast cancer (TNBC) is one of the most aggressive types of breast cancer and needs new promising therapeutic agents due to its lack in responsiveness to hormonal therapies or HER2 targeting drugs due to the absence of progesterone receptor, estrogen receptor, and HER2 receptor. Therefore, developing novel therapeutic agents and/or strategies aimed to prevent TNBC growth and to attenuate its behavior associated with metastasis will at improve patients' well-being ultimately cure the disease. ATP was considered originally as only an intracellular energy source. The concept that ATP is an extracellular messenger was not widely accepted until its receptors was cloned in early 1990s. Subsequently, purinergic signaling was investigated and its association with cell growth and proliferation was discovered. One of ATP analogs, 2&feet;, 3&feet;-O-(4-benzoylbenzoyl)-ATP (BzATP) showed wide range of both in vitro and in vivo tumor suppression such as cell proliferation inhibition and apoptosis induction.;The inhibitory effects on cell proliferation, cell migration, and cell invasion of adenine nucleotides and other adenine agents on BCa were observed in vitro. Colony formation assay revealed a suppression of adenine nucleotides especially BzATP on ability of TNBC cells to form colonies. The pilot in vivo experiment demonstrated tumor growth inhibition effect of BzATP in vivo. These in vivo data confirmed an inhibitory effect of BzATP on TNBC tumor growth in vitro. P2Y11 was identified as a receptor mediating inhibitory effect of BzATP. Further analysis on cell death mechanism revealed that BzATP induced ER stress, autophagy and apoptosis, but not necrosis, through P2Y11 receptor. Unlike autophagy reported in many literatures that it is survival pathway cancer cells exploited to avoid apoptosis, BzATP-induced autophagy may not be a survival mechanism. Remarkably, BzATP did not induce apoptosis in non-cancerous mammary epithelial cells, MCF10A.
机译:乳腺癌(BCa)是美国最常被诊断出的非皮肤癌,也是美国女性死于癌症的第二大原因。在过去的几十年中,加强BCa筛查和早期发现可以提高患者的生存率和患者的幸福感。但是,某些侵略性的BCa类型仍然威胁着BCa患者的健康。三阴性乳腺癌(TNBC)是最激进的乳腺癌类型之一,由于缺乏孕激素受体,雌激素受体和HER2受体而对激素疗法或HER2靶向药物缺乏反应,因此需要新的有前途的治疗剂。因此,开发旨在防止TNBC生长并减弱其与转移有关的行为的新型治疗剂和/或策略将改善患者的健康,最终治愈该疾病。 ATP最初仅被认为是一种细胞内能源。直到1990年代早期克隆了ATP的受体,这一概念才被广泛接受。随后,对嘌呤能信号进行了研究,并发现了其与细胞生长和增殖的关系。 ATP类似物之一2,feet;,3&feet--O-(4-苯甲酰基苯甲酰基)-ATP(BzATP)在体内外抑制肿瘤方面表现出广泛的抑制作用,例如细胞增殖抑制和凋亡诱导;对细胞的抑制作用在体外观察到BCa上腺嘌呤核苷酸和其他腺嘌呤试剂的增殖,细胞迁移和细胞侵袭。集落形成测定揭示了对TNBC细胞形成集落的能力的腺嘌呤核苷酸特别是BzATP的抑制。体内先导实验证明了BzATP在体内具有抑制肿瘤生长的作用。这些体内数据证实了BzATP对体外TNBC肿瘤生长的抑制作用。 P2Y11被确定为介导BzATP抑制作用的受体。对细胞死亡机制的进一步分析表明,BzATP通过P2Y11受体诱导内质网应激,自噬和凋亡,但不引起坏死。与许多文献中报道的自噬不同,它是癌细胞被利用来避免凋亡的生存途径,而BzATP诱导的自噬可能不是生存机制。值得注意的是,BzATP不会在非癌性乳腺上皮细胞MCF10A中诱导凋亡。

著录项

  • 作者

    Lertsuwan, Jomnarong.;

  • 作者单位

    University of Delaware.;

  • 授予单位 University of Delaware.;
  • 学科 Molecular biology.
  • 学位 Ph.D.
  • 年度 2014
  • 页码 197 p.
  • 总页数 197
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号